References
- Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report). 2020.
- British Lung Foundation. Chronic Obstructive Pulmonary Disease (COPD) statistics [cited 2020 Nov 7]. Available from: https://statistics.blf.org.uk/copd.
- Adeloye D, Chua S, Lee C, Global Health Epidemiology Reference Group (GHERG), et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health 2015;5(2):020415. DOI:https://doi.org/10.7189/jogh.05-020415
- Bednarek M, Maciejewski J, Wozniak M, et al. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax 2008;63(5):402–407. DOI:https://doi.org/10.1136/thx.2007.085456
- Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 201106(2):196–204. DOI:https://doi.org/10.7326/0003-4819-106-2-196
- Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114–1121. DOI:https://doi.org/10.1164/rccm.200506-859OC
- Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev. 2001;14(2):336–363. DOI:https://doi.org/10.1128/CMR.14.2.336-363.2001
- Roede BM, Bindels PJ, Brouwer HJ, et al. Antibiotics and steroids for exacerbations of COPD in primary care: Compliance with Dutch guidelines. Br J Gen Pract. 2006;56(530):662–665.
- Shallcross L, Beckley N, Rait G, et al. Antibiotic prescribing frequency amongst patients in primary care: a cohort study using electronic health records. J Antimicrob Chemother. 2017;72(6):1818–1824. DOI:https://doi.org/10.1093/jac/dkx048
- Davison HC, Low JC, Woolhouse ME. What is antibiotic resistance and how can we measure it? Trends Microbiol. 2000;8(12):554–559. DOI:https://doi.org/10.1016/S0966-842X(00)01873-4
- Kraemer SA, Ramachandran A, Perron GG. Antibiotic pollution in the environment: from microbial ecology to public policy. Microorganisms 2019;7(6): 180.DOI:https://doi.org/10.3390/microorganisms7060:
- World Health Organisation. Global action plan on antimicrobial resistance [2021 Mar 17]. Available at: https://www.who.int/publications/i/item/9789241509763. Updated 2016. .
- NHS England. Fighting Antimicrobial Resistance [2021 Mar4]. Available at: https://www.england.nhs.uk/patient-safety/fighting-antimicrobial-resistance/.
- HM Government. Department of Health and Social Care. Contained and controlled: The UK’s 20-year vision for antimicrobial resistance [2021 Mar 3]. Available at: https://www.gov.uk/government/publications/uk-20-year-vision-for-antimicrobial-resistance.
- Kyd JM, McGrath J, Krishnamurthy A. Mechanisms of bacterial resistance to antibiotics in infections of COPD patients. Curr Drug Targets 2011;12(4):521–530. DOI:https://doi.org/10.2174/138945011794751519
- Nightingale CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J. 1997;16(4):438–443. DOI:https://doi.org/10.1097/00006454-199704000-00027
- Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med. 2013;1(3):262–274. DOI:https://doi.org/10.1016/S2213-2600(13)70038-9
- PROSPERO. The prevalence, pattern and impact of antibiotic resistance in COPD: A systematic review 2020 (CRD42020218684). [2021 Mar 10]. Available at: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020218684.
- Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.2. [2021 Mar 10]. Available at: www.training.cochrane.org/handbook.
- Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. DOI:https://doi.org/10.1136/bmj.l4898
- Munn Z, Moola S, Lisy K, et al. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthcare 2015;13(3):147–153. DOI:https://doi.org/10.1097/XEB.0000000000000054
- Guo Z, Chang C, Chen Y, et al. [bacteriology in acute exacerbation in patients hospitalized frequently for acute exacerbation of chronic obstructive pulmonary disease. Zhonghua Yi Xue Za Zhi 2014;94(10):729–732 (in Chinese).
- Estirado C, Ceccato A, Guerrero M, et al. Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease. Respir Res. 2018;19(1):119. DOI:https://doi.org/10.1186/s12931-018-0820-1
- Nseir S, Di Pompeo C, Cavestri B, et al. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome. Crit Care Med. 2006;34(12):2959–2966. DOI:https://doi.org/10.1097/01.CCM.0000245666.28867.C6
- Rodrigo-Troyano A, Suarez-Cuartin G, Peiró M, et al. Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD. Respirology. 2016;21(7):1235–1242. DOI:https://doi.org/10.1111/resp.12825
- Brill SE, Law M, El-Emir E, et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax. 2015;70(10):930–938. DOI:https://doi.org/10.1136/thoraxjnl-2015-207194
- Desai H, Richter S, Doern G, et al. Antibiotic resistance in sputum isolates of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to antibiotic exposure. COPD. 2010;7(5):337–344. DOI:https://doi.org/10.3109/15412555.2010.510162
- Inoue S, Watanuki Y, Miyazawa N, et al. High frequency of β-lactamase-negative, ampicillin-resistant strains of Haemophilus influenzae in patients with chronic bronchitis in Japan. J Infect Chemother. 2010;16(1):72–75. DOI:https://doi.org/10.1007/s10156-009-0020-5
- Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD [published correction appears in N Engl J med. 2012;366(14):1356]. N Engl J Med. 2011;365(8):689–698. DOI:https://doi.org/10.1056/NEJMoa1104623
- Pomares X, Montón C, Bullich M, et al. Clinical and safety outcomes of long-term azithromycin therapy in severe COPD beyond the first year of treatment. Chest 2018;153(5):1125–1133. DOI:https://doi.org/10.1016/j.chest.2018.01.044
- Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361–368. DOI:https://doi.org/10.1016/S2213-2600(14)70019-0
- Pettigrew MM, Tsuji BT, Gent JF, et al. Effect of fluoroquinolones and macrolides on eradication and resistance of Haemophilus influenzae in chronic obstructive pulmonary disease. Antimicrob Agents Chemother. 2016;60(7):4151–4158. DOI:https://doi.org/10.1128/AAC.00301-16
- Montero M, Domínguez M, Orozco-Levi M, et al. Mortality of COPD patients infected with multi-resistant pseudomonas aeruginosa: a case and control study. Infection 2009;37(1):16–19. DOI:https://doi.org/10.1007/s15010-008-8125-9
- Pan W, Yu J, Zhang L, et al. Predictors of in-hospital mortality in patients with acute exacerbation of COPD requiring ventilation: a retrospective study. Int J Clin Exp Med. 2016;9(11):22093–22101.
- Vitacca M, Marino S, Comini L, et al. Bacterial colonization in COPD patients admitted to a rehabilitation respiratory unit and impact on length of stay: a real-life study. COPD. 2018;15(6):581–587. DOI:https://doi.org/10.1080/15412555.2019.1572731
- Liu H, Zheng D, Lin Y, et al. Association of sputum microbiome with clinical outcome of initial antibiotic treatment in hospitalized patients with acute exacerbations of COPD. Pharmacol Res. 2020;160:105095 DOI:https://doi.org/10.1016/j.phrs.2020.105095
- Bae S, Lee J, Lee J, et al. Antimicrobial resistance in haemophilus influenzae respiratory tract isolates in korea: Results of a nationwide acute respiratory infections surveillance. Antimicrob Agents Chemother. 2010;54(1):65–71. DOI:https://doi.org/10.1128/AAC.00966-09
- Hasegawa K, Chiba N, Kobayashi R, et al. Rapidly increasing prevalence of beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis. Antimicrob Agents Chemother. 2004;48(5):1509–1514. DOI:https://doi.org/10.1128/aac.48.5.1509-1514.2004
- Khan MA, Northwood JB, Levy F, et al. Bro {beta}-lactamase and antibiotic resistances in a global cross-sectional study of Moraxella catarrhalis from children and adults. J Antimicrob Chemother. 2010;65(1):91–97. DOI:https://doi.org/10.1093/jac/dkp401
- National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing NICE guideline [NG114]. [internet]. London: National Institute for Health and Care Excellence; 2018. [cited 2021 mar 19]. Available from: www.nice.org.uk/guidance/ng114
- Shimizu K, Yoshii Y, Morozumi M, et al. Pathogens in COPD exacerbations identified by comprehensive real-time PCR plus older methods. Int J Chron Obstruct Pulmon Dis. 2015;10:2009–2016. DOI:https://doi.org/10.2147/COPD.S82752
- Siddiqi A, Sethi S. Optimizing antibiotic selection in treating COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2008;3(1):31–44. DOI:https://doi.org/10.2147/copd.s1089
- Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? Proc Am Thorac Soc. 2004;1(2):109–114. DOI:https://doi.org/10.1513/pats.2306029
- Sawicki GS, Rasouliyan L, Pasta DJ, et al. The impact of incident methicillin resistant S. aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol. 2008;43(11):1117–1123. DOI:https://doi.org/10.1002/ppul.20914
- Goss CH, Muhlebach MS. Review: S. aureus and MRSA in cystic fibrosis. J Cyst Fibros. 2011;10(5):298–306. DOI:https://doi.org/10.1016/j.jcf.2011.06.002
- Cogen J, Emerson J, Sanders DB, et al., for the EPIC Study Group. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol. 2015;50(8):763–770. DOI:https://doi.org/10.1002/ppul.23217
- Sieniawski K, Kaczka K, Rucińska M, et al. Acinetobacter baumannii nosocomial infections. Pol Przegl Chir. 2013;85(9):483–490. DOI:https://doi.org/10.2478/pjs-2013-0075
- Montón C, Prina E, Pomares X, et al. Nebulized colistin and continuous cyclic azithromycin in severe COPD patients with chronic bronchial infection due to Pseudomonas aeruginosa: a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:2365–2373. DOI:https://doi.org/10.2147/COPD.S209513
- Iffat W, Shoaib MH, Muhammad IN, et al. Antimicrobial susceptibility testing of newer quinolones against gram positive and gram negative clinical isolates. Pak J Pharm Sci. 2010;23(3):245–249.
- Kim ES, Hooper DC. Clinical importance and epidemiology of quinolone resistance. Infect Chemother. 2014;46(4):226–238. DOI:https://doi.org/10.3947/ic.2014.46.4.226
- Vollenweider DJ, Frei A, Steurer-Stey C, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;10(10):CD010257. DOI:https://doi.org/10.1002/14651858.CD010257.pub2
- National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: Diagnosis and management. NICE guidelines NG115. [internet]. London: National Institute for Health and Care Excellence; 2018. [cited 2021 mar 16]. Available from: www.nice.org.uk/guidance/ng115.
- Zhang H, Tan M, Qiu A, et al. Antibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: a network Meta-analysis. BMC Pulm Med. 2017;17(1) DOI:https://doi.org/10.1186/s12890-017-0541-0
- Mac Aogáin M, Lau KJX, Cai Z, et al. Metagenomics reveals a core macrolide resistome related to microbiota in chronic respiratory Disease. Am J Respir Crit Care Med. 2020;202(3):433–447. DOI:https://doi.org/10.1164/rccm.201911-2202OC
- Maddi S, Kolsum U, Jackson S, et al. Ampicillin resistance in haemophilus influenzae from COPD patients in the UK. Int J COPD. 2017;12:1507–1518. DOI:https://doi.org/10.2147/COPD.S135338
- Pettigrew MM, Gent JF, Revai K, Patel JA, Chonmaitree T. Microbial interactions during upper respiratory tract infections. Emerg Infect Dis. 2008;14(10):1584–1591. DOI:https://doi.org/10.3201/eid1410.080119
- Pfaller MA, Ehrhardt AF, Jones RN. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: Microbiology from the medical office practice environment. Am J Med. 2001;111:4S–38S.
- Pfaller MA, Jones RN. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: Report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. Diag Microbiol Infect Dis. 2002;44(1):77–84. DOI:https://doi.org/10.1016/s0732-8893(02)00446-7
- Querol-Ribelles J, Molina J, Naberan K, Esteban E, Herreras A, Garcia-de-Lomas J. Discrepancy between antibiotics administered in acute exacerbations of chronic bronchitis and susceptibility of isolated pathogens in respiratory samples: Multicentre study in the primary care setting. Int J Antimicrob Agents. 2006;28(5):472–476. DOI:https://doi.org/10.1016/j.ijantimicag.2006.05.034
- Gallego M, Pomares X, Espasa M, et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: Characterization and risk factors. BMC Pulm Med. 2014;14(1):103. DOI:https://doi.org/10.1186/1471-2466-14-103
- DeAbate CA, Bettis R, Munk ZM, et al. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Ther. 1999;21(1):172–188. DOI:https://doi.org/10.1016/S0149-2918(00)88277-6
- Grossman RF, Beaupre A, LaForge J, Lampron N, Hanna K. A prospective randomised parallel single-blind comparison of oral ciprofloxacin with oral cotrimoxazole in the treatment of respiratory tract infections in patients with chronic obstructive lung disease. Drug Invest. 1994;8(2):110–117. DOI:https://doi.org/10.1007/BF03257434
- Kahn JB, Khashab M, Ambruzs M. Study entry microbiology in patients with acute bacterial exacerbation of chronic bronchitis in a clinical trial stratifying by disease severity. Curr Med Res Opin. 2007;23(1):1–7. DOI:https://doi.org/10.1185/030079907X159515
- Agmy G, Mohamed S, Gad Y, Farghally E, Mohammedin H, Rashed H. Bacterial profile, antibiotic sensitivity and resistance of lower respiratory tract infections in upper Egypt. Mediterranean J Hematol Infect Dis. 2013;5(1). DOI:https://doi.org/10.4084/mjhid.2013.056
- Aogain MM, Zhao C, Purbojati RW, et al. The airway ‘resistome’ in chronic respiratory disease: A metagenomics approach. European Respiratory Journal. Conference: 29th International Congress of the European Respiratory Society, ERS, Spain. 2019;54.
- Blasi F, Farrell DJ, Dubreuil L. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: The prospective resistant organism tracking and epidemiology for the ketolide telithromycin study year 5 (2003–2004). Diagn Microbiol Infect Dis. 2009;63(3):302–308. DOI:https://doi.org/10.1016/j.diagmicrobio.2008.11.012
- Butt HL, Cripps AW, Clancy RL. In vitro susceptibility patterns of nonserotypable haemophilus influenzae from patients with chronic bronchitis. Pathology. 1997;29(1):72–75. DOI:https://doi.org/10.1080/00313029700169584
- Casellas JM, Gilardoni M, Tome G, et al. Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections. J Antimicrob Chemother. 1999;43:37–42. DOI:https://doi.org/10.1093/jac/43.suppl_3.37
- Chen L, Xie Z, Yang Y. Composition of pathogenic bacteria of chronic obstructive pulmonary disease patients and drug resistance of gram-negative bacilli for various antibiotics. Biomed Res. 2018;29(4) DOI:https://doi.org/10.4066/biomedicalresearch.29-17-3313
- Ding YL, Yao WZ, Zhou QT, Chen YH, Ning YZ. Effect of mechanical ventilation beginning time after admission and ventilation duration on pathogens and antibiotic susceptibility of lower respiratory tract infection in chronic obstructive pulmonary disease patients [Chinese]. Chin J Antibiot. 2011;36(2):154–159
- Domenech A, Puig C, Martí S, et al. Infectious etiology of acute exacerbations in severe COPD patients. J Infect. 2013;67(6):516–523. DOI:https://doi.org/10.1016/j.jinf.2013.09.003
- Domenech A, Ardanuy C, Calatayud L, et al. Serotypes and genotypes of streptococcus pneumoniae causing pneumonia and acute exacerbations in patients with chronic obstructive pulmonary disease. J Antimicrob Chemother. 2011;66(3):487–493. DOI:https://doi.org/10.1093/jac/dkq480
- Domenech A, Ardanuy C, Pallares R, et al. Some pneumococcal serotypes are more frequently associated with relapses of acute exacerbations in COPD patients. PLoS One. 2013;8(3):e59027 DOI:https://doi.org/10.1371/journal.pone.0059027
- Domenech A, Ardanuy C, Tercero A, Garcia-Somoza D, Santos S, Linares J. Dynamics of the pneumococcal population causing acute exacerbations in COPD patients in a Barcelona hospital (2009–12): Comparison with 2001-04 and 2005-08 periods. J Antimicrob Chemother. 2014;69(4):932–939. DOI:https://doi.org/10.1093/jac/dkt476
- Engler K, Muhlemann K, Garzoni C, Pfahler H, Geiser T, Von Garnier C. Colonisation with pseudomonas aeruginosa and antibiotic resistance patterns in COPD patients. Swiss Med Wkly. 2011;142. DOI:https://doi.org/10.4414/smw.2012.13509
- Erkan L, Uzun O, Findik S, Katar D, Sanic A, Atici AG. Role of bacteria in acute exacerbations of chronic obstructive pulmonary disease. Int J COPD. 2008;3(3):463–467
- Ewig S, Soler N, Gonzalez J, Celis R, El-Ebiary M, Torres A. Evaluation of antimicrobial treatment in mechanically ventilated patients with severe chronic obstructive pulmonary disease exacerbations. Crit Care Med. 2000;28(3):692–697
- Firdaus H, Khan NA, Fatima N, Shameem M, Bhargava R, Ahmad Z. Acute exacerbation of chronic obstructive pulmonary disease: Phenotypic screening and sensitivity of microbiological profile. J Clin Diagn Res. 2020; 14(6):LC15–LC20.
- Glogovska PT, Ivanova ZI, Popova TP, et al. Sputum isolates from ambulatory patients with chronic obstructive pulmonary disease—frequent pathogens and antibiotic resistance. J IMAB - Ann Proceed. 2015;21(2):770–774. DOI:https://doi.org/10.5272/jimab.2015212.770
- Grochowalska A, Koziol-Montewka M, Sobieszczanska A. Analysis of acinetobacter baumannii resistance patterns in patients with chronic obstructive pulmonary disease (COPD) in terms of choice of effective empiric antibiotic therapy. Ann Agric Environ Med. 2017;24(2):307–311. DOI:https://doi.org/10.26444/aaem/74710
- Hui DS, Ip M, Ling T, et al. A multicentre surveillance study on the characteristics, bacterial aetiologies and in vitro antibiotic susceptibilities in patients with acute exacerbations of chronic bronchitis. Respirology. 2011;16(3):532–539 DOI:https://doi.org/10.1111/j.1440-1843.2011.01943.x
- Kennedy M, Ramsheh MY, Williams CML, et al. Face mask sampling reveals antimicrobial resistance genes in exhaled aerosols from patients with chronic obstructive pulmonary disease and healthy volunteers. BMJ Open Resp Res. 2018;5(1):e000321. DOI:https://doi.org/10.1136/bmjresp-2018-000321
- Khilnani GC, Dubey D, Hadda V, et al. Predictors and microbiology of ventilator-associated pneumonia among patients with exacerbation of chronic obstructive pulmonary disease. Lung India. 2019;36(6):506–511. DOI:https://doi.org/10.4103/lungindia.lungindia_13_19
- Kuwal A, Joshi V, Dutt N, Singh S, Agarwal KC, Purohit G. A prospective study of bacteriological etiology in hospitalized acute exacerbation of COPD patients: Relationship with lung function and respiratory failure. Turk Toraks Dergisi/Turkish Thoracic J. 2018;19(1):19–27. DOI:https://doi.org/10.5152/TurkThoracJ.2017.17035
- Larsen MV, Janner JH, Nielsen SD, Friis-Møller A, Ringbaek T, Lange P. Bacteriology in acute exacerbation of chronic obstructive pulmonary disease in patients admitted to hospital. Scand J Infect Dis. 2009;41(1):26–32. DOI:https://doi.org/10.1080/00365540802484828
- Ma X, Cui J, Wang J, et al. Multicentre investigation of pathogenic bacteria and antibiotic resistance genes in Chinese patients with acute exacerbation of chronic obstructive pulmonary disease. J Int Med Res. 2015;43(5):699–710. DOI:https://doi.org/10.1177/0300060515587577
- Nian L, Liangyi X, Gang J, Wei L, Yongliang J. Analysis on constituents and drug resistance of pathogenic bacteria causing chronic obstructive pulmonary disease. Biomed Res (India). 2017;28(20):8939–8942.
- Perez-Trallero E, Marimon JM, Larruskain J, Alonso M, Ercibengoa M. Antimicrobial susceptibilities and serotypes of streptococcus pneumoniae isolates from elderly patients with pneumonia and acute exacerbation of chronic obstructive pulmonary disease. Antimicrob Agent Chemother. 2011;55(6):2729–2734. DOI:https://doi.org/10.1128/AAC.01546-10
- Rodrigo-Troyano A, Melo V, Marcos PJ, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease patients with frequent hospitalized exacerbations: a prospective multicentre study. Respiration. 2018;96(5):417–424. DOI:https://doi.org/10.1159/000490190
- Sharma P, Narula S, Sharma K, Lohchab K, Kumar N. Sputum bacteriology and antibiotic sensitivity pattern in COPD exacerbation in india. Egypt J Chest Dis Tubercul. 66(4):593–597. DOI:https://doi.org/10.1016/j.ejcdt.2017.08.003
- Shoji H, Vazquez-Sanchez D, Gonzalez-Diaz A, et al. Overview of pneumococcal serotypes and genotypes causing diseases in patients with chronic obstructive pulmonary disease in a Spanish hospital between 2013 and 2016. Infect Drug Resist. 2018;11:1387–1400. DOI:https://doi.org/10.2147/IDR.S165093
- Shrestha R, Shrestha B, Shakya Shrestha S, Pant A, Prajapati B, Karmacharya BM. Study of pre-disposing factors of acute exacerbation of chronic obstructive pulmonary disease and antibiotic prescribing pattern with reference to antibiotic sensitivity test. Kathmandu Univ Med J. 13(51):259–264. DOI:https://doi.org/10.3126/kumj.v13i3.16817
- Srinivasan SV, Ahmed JS. Gram negative organisms as a cause of acute exacerbation of ‘COPD’ and assess the multi drug resistant in the gram-negative isolates. Int J Res Ayurveda Pharm. 2017;8(2):91–94. DOI:https://doi.org/10.7897/2277-4343.08272
- Vandevelde NM, Tulkens PM, et al. Characterisation of a collection of streptococcus pneumoniae isolates from patients suffering from acute exacerbations of chronic bronchitis: In vitro susceptibility to antibiotics and biofilm formation in relation to antibiotic efflux and serotypes/serogroups. Int J Antimicrob Agent. 2014;44(3):209–217. DOI:https://doi.org/10.1016/j.ijantimicag.2014.05.016
- Varon F, Torres-Caro C, Herrera-Diaz C, et al. Microbiological characterization of severe exacerbations in chronic obstructive pulmonary disease (COPD) in patients admitted to the ICU with or without associated pneumonia: A retrospective cross-sectional study. Infectio. 2019;23(4):307–312. DOI:https://doi.org/10.22354/in.v23i4.803
- Xu P, Song W, Liu Y, Pi J, Li Y, Yang H. Analysis of bacterial pathogens isolated from lower respiratory tract in patients with acute exacerbation of chronic obstructive pulmonary diseases [Chinese]. Chinese J Infect Chemother. 10(2):108–111.
- Ye F, He LX, Cai BQ, et al. Spectrum and antimicrobial resistance of common pathogenic bacteria isolated from patients with acute exacerbation of chronic obstructive pulmonary disease in mainland of china. Chin Med J. 2013;126(12):2207–2214.
- Zhao JN, Zhang XX, He XC, et al. Multidrug-resistant tuberculosis in patients with chronic obstructive pulmonary disease in china. PLoS One. 2015;10(8):e0135205. DOI:https://doi.org/10.1371/journal.pone.0135205